Patents by Inventor Amy S. Rosenberg

Amy S. Rosenberg has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • REGULATORY T CELL EPITOPES
    Publication number: 20230212512
    Abstract: The present is directed to compositions comprising regulatory T cell epitopes, wherein said epitopes comprise a polypeptide comprising at least a portion of SEQ NOS: 1-14, fragments and/or variants thereof, as well as methods of producing and using the same.
    Type: Application
    Filed: August 23, 2022
    Publication date: July 6, 2023
    Inventors: William Martin, Amy S. Rosenberg
  • Regulatory T cell epitopes
    Patent number: 11441122
    Abstract: The present is directed to compositions comprising regulatory T cell epitopes, wherein said epitopes comprise a polypeptide comprising at least a portion of SEQ NOS: 1-14, fragments and/or variants thereof, as well as methods of producing and using the same.
    Type: Grant
    Filed: October 5, 2018
    Date of Patent: September 13, 2022
    Assignees: EpiVax Inc., The United States of America, as Represented by the Secretary, Department of Health and Human Services Food and Drug Administration
    Inventors: William Martin, Amy S. Rosenberg
  • REGULATORY T CELL EPITOPES
    Publication number: 20200308542
    Abstract: The present is directed to compositions comprising regulatory T cell epitopes, wherein said epitopes comprise a polypeptide comprising at least a portion of SEQ NOS: 1-14, fragments and/or variants thereof, as well as methods of producing and using the same.
    Type: Application
    Filed: October 5, 2018
    Publication date: October 1, 2020
    Inventors: William Martin, Amy S. Rosenberg
  • Oligonucleotides of human endogenous retrovirus 9 (ERV-9) long terminal repeat (LTR) and methods of use
    Patent number: 8680065
    Abstract: Described herein are oligonucleotides that target the human endogenous retrovirus-9 (ERV-9) long terminal repeat (LTR). The ERV-9 LTR oligonucleotides specifically hybridize with either the coding strand or non-coding strand of ERV-9 LTR. It is disclosed herein that ERV-9 LTR oligonucleotides inhibit the proliferation of cancer cells, including breast cancer, liver cancer, prostate cancer, fibrosarcoma and myeloid cancer cells. Also described herein are methods of treating a subject diagnosed with cancer comprising administering to the subject an ERV-9 LTR oligonucleotide. In some examples, the methods further comprise administering a second therapeutic agent, such as an antisense compound or a chemotherapeutic agent.
    Type: Grant
    Filed: September 11, 2009
    Date of Patent: March 25, 2014
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Lai Xu, Amy S. Rosenberg, Abdel Elkahloun, Fabio Candotti
  • OLIGONUCLEOTIDES TARGETING HUMAN ENDOGENOUS RETROVIRUS 9 (ERV-9) LONG TERMINAL REPEAT (LTR) AND METHODS OF USE
    Publication number: 20110166204
    Abstract: Described herein are oligonucleotides that target the human endogenous retrovirus-9 (ERV-9) long terminal repeat (LTR). The ERV-9 LTR oligonucleotides specifically hybridize with either the coding strand or non-coding strand of ERV-9 LTR. It is disclosed herein that ERV-9 LTR oligonucleotides inhibit the proliferation of cancer cells, including breast cancer, liver cancer, prostate cancer, fibrosarcoma and myeloid cancer cells. Also described herein are methods of treating a subject diagnosed with cancer comprising administering to the subject an ERV-9 LTR oligonucleotide. In some examples, the methods further comprise administering a second therapeutic agent, such as an antisense compound or a chemotherapeutic agent.
    Type: Application
    Filed: September 11, 2009
    Publication date: July 7, 2011
    Inventors: Lai Xu, Amy S. Rosenberg, Abdel Elkahloun, Fabio Candotti